Search In this Thesis
   Search In this Thesis  
العنوان
Three Years Clinico-Epidemiological Study of Breast Cancer Patients at Clinical Oncology Department, Tanta University /
المؤلف
Farrag, Amira Abd-Elfattah Mostafa.
هيئة الاعداد
باحث / اميرة عبد الفتاح مصطفى فراج
مشرف / علاء محمد مارية
مشرف / فاطمة غريب خيرالله
مشرف / رباب محمود ابو صباع
الموضوع
Clinical Oncology. Nuclear.
تاريخ النشر
2024.
عدد الصفحات
157 p. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
علم الأورام
تاريخ الإجازة
25/8/2024
مكان الإجازة
جامعة طنطا - كلية الطب - علاج الاورام والطب النووي
الفهرس
Only 14 pages are availabe for public view

from 186

from 186

Abstract

Breast cancer is the most commonly diagnosed cancer in females and the second leading cause of cancer death amond women, worldwide. In Egypt, breast cancer has the highest incidence in female cancer patients. Incidence, mortality and survival rates of breast cancer vary considerably among different parts of the world, which could be due to many factors such a population structure, lifestyle, genetics factors and environment. Breast cancer represented 20.4% of all cases presented during the period from Jan 2019 to Jan 2022 in our department. The majority of patients in our study were from El- Gharbia followed by El-menofia with the median age was 53.4 years. Postmenopausal patients were higher than premenopausal. Hypertension was the most co-existing comorbid illness followed by diabetes. Positive family history of breast cancer was reported in 10.7% of patients and 12.2% of patients were positive for other malignancies. Half of patients were left-sided, with 66.6% supra-areolar in position. Stage II was the most common presenting stage 43%. Bone metastasis was found in 84% of de novo MBC cases. Invasive ductal carcinoma was the most common pathological subtype and grade II was the most frequent. Intraductal component and PNI were negative in most patients but LVI was positive in most patients. Most cases were luminal, followed by TNBC. Surgery was done in the majority of patients with MRM followed by BCS. Chemotherapy was offered in most cases whether neoadjuvant, adjuvant or palliative. Herceptin was given in most patients with HER2 positive. Radiotherapy whether adjuvant or palliative was offered in most cases. Hormonal therapy was offered in most patients with HR positive. Over 90% of cases were still alive by the end of the study. The mean OS was 184.8 months, the median DFS was 66 months and the median PFS was 39.6, 19.7% of non-metastatic patients developed metastasis whether solitary or multiple and bone was the most common site of metastasis followed by lung.